A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate
(50 milligrams[mg], 100mg, and 200mg per day) compared with placebo in the prevention of
migraine. The study will also assess the dose response relationship and the efficacy of
treatment with topiramate versus placebo on Health-Related Quality of Life.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.